385 related articles for article (PubMed ID: 8001943)
21. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
22. Risk behaviours of young Indo-Chinese injecting drug users in Sydney and Melbourne.
Maher L; Sargent P; Higgs P; Crofts N; Kelsall J; Le TT
Aust N Z J Public Health; 2001; 25(1):50-4. PubMed ID: 11297303
[TBL] [Abstract][Full Text] [Related]
23. Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan.
Yen YF; Yen MY; Su LW; Li LH; Chuang P; Jiang XR; Deng CY
BMC Public Health; 2012 Dec; 12():1066. PubMed ID: 23227904
[TBL] [Abstract][Full Text] [Related]
24. Risk of hepatitis C infection among injection drug users in Mizoram, India.
Chelleng PK; Borkakoty BJ; Chetia M; Das HK; Mahanta J
Indian J Med Res; 2008 Nov; 128(5):640-6. PubMed ID: 19179686
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users.
Roy KM; Goldberg DJ; Hutchinson S; Cameron SO; Wilson K; MacDonald L
J Med Virol; 2004 Sep; 74(1):62-6. PubMed ID: 15258969
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of hepatitis C virus infection among injecting drug users in Australia.
Crofts N; Jolley D; Kaldor J; van Beek I; Wodak A
J Epidemiol Community Health; 1997 Dec; 51(6):692-7. PubMed ID: 9519134
[TBL] [Abstract][Full Text] [Related]
27. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
28. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.
Liu Y; Liu Y; Zou X; Chen W; Ling L
BMJ Open; 2017 Jul; 7(7):e015524. PubMed ID: 28710214
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B and C in New South Wales prisons: prevalence and risk factors.
Butler TG; Dolan KA; Ferson MJ; McGuinness LM; Brown PR; Robertson PW
Med J Aust; 1997 Feb; 166(3):127-30. PubMed ID: 9059433
[TBL] [Abstract][Full Text] [Related]
30. Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro.
Judd A; Rhodes T; Johnston LG; Platt L; Andjelkovic V; Simić D; Mugosa B; Simić M; Zerjav S; Parry RP; Parry JV
BMC Infect Dis; 2009 Feb; 9():14. PubMed ID: 19203380
[TBL] [Abstract][Full Text] [Related]
31. Seroprevalence of anti-hepatitis C virus (anti-HCV) antibody and HCV-related risk in injecting drug users in northern India: comparison with non-injecting drug users.
Basu D; Kumar V; Sharma AK; Barnwal PK; Mattoo SK
Asian J Psychiatr; 2013 Feb; 6(1):52-5. PubMed ID: 23380318
[TBL] [Abstract][Full Text] [Related]
32. High HIV testing and low HIV prevalence among injecting drug users attending the Sydney Medically Supervised Injecting Centre.
Salmon AM; van Beek I; Amin J; Grulich A; Maher L
Aust N Z J Public Health; 2009 Jun; 33(3):280-3. PubMed ID: 19630850
[TBL] [Abstract][Full Text] [Related]
33. HIV, hepatitis B and sexual practices in the street-recruited injecting drug users of Calcutta: risk perception versus observed risks.
Panda S; Chatterjee A; Bhattacharjee S; Ray B; Saha MK; Bhattacharya SK
Int J STD AIDS; 1998 Apr; 9(4):214-8. PubMed ID: 9598748
[TBL] [Abstract][Full Text] [Related]
34. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project.
Caiaffa WT; Mingoti SA; Proietti FA; Carneiro-Proietti AB; Silva RC; Lopes AC; Doneda D
J Urban Health; 2003 Mar; 80(1):106-14. PubMed ID: 12612100
[TBL] [Abstract][Full Text] [Related]
35. Low knowledge and perceived Hepatitis C risk despite high risk behaviour among injection drug users in Kathmandu, Nepal.
Loewinger G; Sharma B; Karki DK; Khatiwoda P; Kainee S; Poudel KC
Int J Drug Policy; 2016 Jul; 33():75-82. PubMed ID: 27318773
[TBL] [Abstract][Full Text] [Related]
36. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.
Tun W; Vu L; Adebajo SB; Abiodun L; Sheehy M; Karlyn A; Njab J; Ahonsi B; Issa BK; Idogho O
Int J STD AIDS; 2013 Aug; 24(8):619-25. PubMed ID: 23970571
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh.
Shirin T; Ahmed T; Iqbal A; Islam M; Islam MN
J Health Popul Nutr; 2000 Dec; 18(3):145-50. PubMed ID: 11262767
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.
Hahn JA; Page-Shafer K; Lum PJ; Ochoa K; Moss AR
Hepatology; 2001 Jul; 34(1):180-7. PubMed ID: 11431749
[TBL] [Abstract][Full Text] [Related]
40. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
